These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39147143)

  • 41. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
    Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
    Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
    [No Abstract]   [Full Text] [Related]  

  • 43. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.
    Zhou D; Chan JF; Zhou B; Zhou R; Li S; Shan S; Liu L; Zhang AJ; Chen SJ; Chan CC; Xu H; Poon VK; Yuan S; Li C; Chik KK; Chan CC; Cao J; Chan CY; Kwan KY; Du Z; Lau TT; Zhang Q; Zhou J; To KK; Zhang L; Ho DD; Yuen KY; Chen Z
    Cell Host Microbe; 2021 Apr; 29(4):551-563.e5. PubMed ID: 33657424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters.
    Fagre AC; Manhard J; Adams R; Eckley M; Zhan S; Lewis J; Rocha SM; Woods C; Kuo K; Liao W; Li L; Corper A; Challa D; Mount E; Tumanut C; Tjalkens RB; Aboellail T; Fan X; Schountz T
    Front Immunol; 2020; 11():614256. PubMed ID: 33391285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
    Chen RE; Zhang X; Case JB; Winkler ES; Liu Y; VanBlargan LA; Liu J; Errico JM; Xie X; Suryadevara N; Gilchuk P; Zost SJ; Tahan S; Droit L; Turner JS; Kim W; Schmitz AJ; Thapa M; Wang D; Boon ACM; Presti RM; O'Halloran JA; Kim AHJ; Deepak P; Pinto D; Fremont DH; Crowe JE; Corti D; Virgin HW; Ellebedy AH; Shi PY; Diamond MS
    Nat Med; 2021 Apr; 27(4):717-726. PubMed ID: 33664494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A highly potent antibody effective against SARS-CoV-2 variants of concern.
    Fenwick C; Turelli P; Perez L; Pellaton C; Esteves-Leuenberger L; Farina A; Campos J; Lana E; Fiscalini F; Raclot C; Pojer F; Lau K; Demurtas D; Descatoire M; Joo VS; Foglierini M; Noto A; Abdelnabi R; Foo CS; Vangeel L; Neyts J; Du W; Bosch BJ; Veldman G; Leyssen P; Thiel V; LeGrand R; Lévy Y; Trono D; Pantaleo G
    Cell Rep; 2021 Oct; 37(2):109814. PubMed ID: 34599871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect
    Amanat F; Strohmeier S; Lee WH; Bangaru S; Ward AB; Coughlan L; Krammer F
    mBio; 2021 Aug; 12(4):e0100221. PubMed ID: 34311574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
    Chen J; Huang R; Nie Y; Wen X; Wu Y
    Virol Sin; 2020 Dec; 35(6):713-724. PubMed ID: 33394351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.
    Chen Z; Zhang P; Matsuoka Y; Tsybovsky Y; West K; Santos C; Boyd LF; Nguyen H; Pomerenke A; Stephens T; Olia AS; Zhang B; De Giorgi V; Holbrook MR; Gross R; Postnikova E; Garza NL; Johnson RF; Margulies DH; Kwong PD; Alter HJ; Buchholz UJ; Lusso P; Farci P
    Cell Rep; 2022 Nov; 41(5):111528. PubMed ID: 36302375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
    Hoffmann M; Krüger N; Schulz S; Cossmann A; Rocha C; Kempf A; Nehlmeier I; Graichen L; Moldenhauer AS; Winkler MS; Lier M; Dopfer-Jablonka A; Jäck HM; Behrens GMN; Pöhlmann S
    Cell; 2022 Feb; 185(3):447-456.e11. PubMed ID: 35026151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
    Cong Y; Mucker EM; Perry DL; Dixit S; Kollins E; Byrum R; Huzella L; Kim R; Josleyn M; Kwilas S; Stefan C; Shoemaker CJ; Koehler J; Coyne S; Delp K; Liang J; Drawbaugh D; Hischak A; Hart R; Postnikova E; Vaughan N; Asher J; St Claire M; Hanson J; Schmaljohn C; Eakin AE; Hooper JW; Holbrook MR
    Antiviral Res; 2023 May; 213():105589. PubMed ID: 37003305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model.
    Halfmann PJ; Kuroda M; Armbrust T; Accola M; Valdez R; Kowalski-Dobson T; Rehrauer W; Gordon A; Kawaoka Y
    Cell Rep; 2022 Feb; 38(7):110394. PubMed ID: 35139368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.
    Yamin R; Jones AT; Hoffmann HH; Schäfer A; Kao KS; Francis RL; Sheahan TP; Baric RS; Rice CM; Ravetch JV; Bournazos S
    Nature; 2021 Nov; 599(7885):465-470. PubMed ID: 34547765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
    Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H
    Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the therapeutic action of original antiviral drug in SARS-CoV-2.
    Melkonian AK; Hakobyan GV
    Biotechnol Appl Biochem; 2024 Oct; 71(5):1057-1069. PubMed ID: 38710664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
    Wheatley AK; Pymm P; Esterbauer R; Dietrich MH; Lee WS; Drew D; Kelly HG; Chan LJ; Mordant FL; Black KA; Adair A; Tan HX; Juno JA; Wragg KM; Amarasena T; Lopez E; Selva KJ; Haycroft ER; Cooney JP; Venugopal H; Tan LL; O Neill MT; Allison CC; Cromer D; Davenport MP; Bowen RA; Chung AW; Pellegrini M; Liddament MT; Glukhova A; Subbarao K; Kent SJ; Tham WH
    Cell Rep; 2021 Oct; 37(2):109822. PubMed ID: 34610292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure-guided antibody cocktail for prevention and treatment of COVID-19.
    Su SC; Yang TJ; Yu PY; Liang KH; Chen WY; Yang CW; Lin HT; Wang MJ; Lu RM; Tso HC; Chung MJ; Hsieh TY; Chang YL; Lin SC; Hsu FY; Ke FY; Wu YH; Hwang YC; Liu IJ; Liang JJ; Liao CC; Ko HY; Sun CP; Wu PY; Jan JT; Chang YC; Lin YL; Tao MH; Hsu SD; Wu HC
    PLoS Pathog; 2021 Oct; 17(10):e1009704. PubMed ID: 34673836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo.
    Rhodin MHJ; Reyes AC; Balakrishnan A; Bisht N; Kelly NM; Gibbons JS; Lloyd J; Vaine M; Cressey T; Crepeau M; Shen R; Manalo N; Castillo J; Levene RE; Leonard D; Zang T; Jiang L; Daniels K; Cox RM; Lieber CM; Wolf JD; Plemper RK; Leist SR; Scobey T; Baric RS; Wang G; Goodwin B; Or YS
    Nat Commun; 2024 Aug; 15(1):6503. PubMed ID: 39090095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant.
    Ryu DK; Song R; Kim M; Kim YI; Kim C; Kim JI; Kwon KS; Tijsma AS; Nuijten PM; van Baalen CA; Hermanus T; Kgagudi P; Moyo-Gwete T; Moore PL; Choi YK; Lee SY
    Biochem Biophys Res Commun; 2021 Aug; 566():135-140. PubMed ID: 34119826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.